Rocket Pharmaceuticals
Agent53Agent Readiness: 53/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust91Data Trust: 91/100. Top 25%. Measured by StartupHub.ai. Median 61.A biotechnology company developing genetic therapies for rare disorders.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
Rocket Pharmaceuticals, Inc. is a fully integrated, commercial-stage biotechnology company focused on advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need. The company has recently strengthened its financial position through the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million.
Listed competitors
Ophthalmic pharmaceutical company developing novel treatments for ocular diseases.
Gene therapy company developing transformative treatments for severe genetic diseases.
Biopharmaceutical company developing novel therapies for rare and ultra-rare genetic diseases.
Vaxart is a clinical-stage biotechnology company developing oral vaccines for infectious diseases.
Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.
Biopharmaceutical company focused on developing RNA-targeted therapies for rare genetic diseases.
A biopharmaceutical company focused on developing novel therapies.
Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.
Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.
Clinical-stage biopharmaceutical company developing gene therapies for rare genetic diseases.
Gene therapy company developing treatments for rare inherited diseases.
RD-Biotech develops innovative solutions for drug discovery and development using advanced biotechnology.
Biotechnology company developing gene therapies and regenerative medicine for heart disease.
A global biotechnology company focused on developing and commercializing therapies for rare genetic diseases.
A global pharmaceutical and biotechnology corporation developing innovative medicines and vaccines for various therapeutic areas.
Key facts
- Website
- rocketpharma.com
- Headquarters
- Cranbury, New Jersey, USA
- Founded
- 2015
- Employees
- 100
- Total funding
- $533M (Debt)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 6 Oct 2026 | Debt | $150M | Hercules Capital, Inc. |
| 20 Sept 2022 | Acquisition | $53M | |
| 1 Dec 2020 | Public Equity Offering | $300M | |
| 1 Apr 2019 | Private Placement/Follow on | $30M |
Tech stack
Detected on rocketpharma.com, last scanned 31 Oct 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Tag Manager
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Mimecast
Rocket Pharmaceuticals scores 52. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Rocket Pharmaceuticals trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Rocket Pharmaceuticals is 91 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Rocket Pharmaceuticals raised?
Rocket Pharmaceuticals has raised a total of $533M in funding. The most recent round on record is Debt.
How many employees does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has approximately 100 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Rocket Pharmaceuticals
